PA
VRDN icon

Profund Advisors’s Viridian Therapeutics VRDN Stock Holding History

Profund Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
54,773
-8,568
-14% -$138K 0.03% 348
2026
Q1 		$1.24M Buy
63,341
+25,827
+69% +$767K 0.05% 293
2025
Q4 		$1.17M Buy
37,514
+22,183
+145% +$608K 0.04% 316
2025
Q3 		$331K Sell
15,331
-1,134
-7% -$20.5K 0.01% 692
2025
Q2 		$230K Sell
16,465
-5,878
-26% -$79.8K 0.01% 824
2025
Q1 		$301K Sell
22,343
-11,047
-33% -$188K 0.01% 670
2024
Q4 		$640K Buy
33,390
+14,934
+81% +$325K 0.02% 404
2024
Q3 		$420K Sell
18,456
-8,534
-32% -$140K 0.02% 612
2024
Q2 		$351K Sell
26,990
-36,021
-57% -$499K 0.01% 630
2024
Q1 		$1.1M Buy
63,011
+30,020
+91% +$582K 0.04% 331
2023
Q4 		$719K Sell
32,991
-10,968
-25% -$173K 0.03% 408
2023
Q3 		$674K Sell
43,959
-211
-0.5% -$4.03K 0.04% 385
2023
Q2 		$1.05M Buy
44,170
+11,270
+34% +$289K 0.06% 305
2023
Q1 		$837K Buy
+32,900
New +$1.05M 0.05% 348

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Profund Advisors's VRDN Position: Q2 2026 in Review

Profund Advisors reduced its Viridian Therapeutics (VRDN) stake by 14% in Q2 2026, selling an estimated $138K and leaving 54,773 shares worth $1.01M. The position accounts for 0.03% of the portfolio, ranked #348.

Profund Advisors first reported a position in VRDN in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.24M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Profund Advisors held 54,773 shares of Viridian Therapeutics worth $1.01M as of Q2 2026.
  • Profund Advisors sold 8,568 Viridian Therapeutics shares in Q2 2026, an estimated $138K.
  • Viridian Therapeutics made up 0.03% of Profund Advisors's portfolio in Q2 2026, its #348 holding.
  • Profund Advisors first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Viridian Therapeutics position peaked at $1.24M in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.